Fig. 3.
Recipient immunization with irradiated unmodified 205 cells increases GVT activity and prevents death from tumor.
One month after C3H.SW→ C57BL/6 BMT, recipients (205-immune, n = 6) were immunized with 50 Gy-irradiated unmodified 205 cells. Control recipients (nonimmune, n = 6) were not immunized. One week after the first vaccine, micrometastases were established in all recipients by intravenous injection of 1 × 105 205 tumor cells, and 205-immune recipients received 3 more vaccines at weekly intervals. Lung nodules were counted after death or after day 100 for each recipient. 205-immune recipients had significantly enhanced survival (A, P = .0016) and significant reduction of lung nodules (B,P = .0022) compared to nonimmune recipients.
